MedTrace Logo

Phase III Study to Evaluate the Efficacy and Safety of AD-209

NCT06348576 · Status: RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 280

Last updated 2024-05-21

No results posted yet for this study

Summary

The purpose of this study is to evaluate the efficacy and safety of AD-209

Conditions

  • Hypertension,Essential

Interventions

DRUG

AD-209

PO, Once daily(QD), 8weeks

DRUG

AD-2091

PO, Once daily(QD), 8weeks

DRUG

AD-209 Placebo

PO, Once daily(QD), 8weeks

DRUG

AD-2091 Placebo

PO, Once daily(QD), 8weeks

Sponsors & Collaborators

  • Addpharma Inc.

    lead INDUSTRY

Principal Investigators

  • Chang Gyu Park, M.D., Ph.D · Korea University Guro Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-05-20
Primary Completion
2025-02-28
Completion
2025-02-28

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06348576 on ClinicalTrials.gov